重组人血管内皮抑制素联合放化疗治疗局部晚期头颈部鳞癌

尚艺泰; 杨洁; 李磊; 李晓江

重组人血管内皮抑制素联合放化疗治疗局部晚期头颈部鳞癌

昆明医科大学第三附属医院头颈外科云南省头颈外科

基金项目:

基金：云南省科技厅-昆明医科大学应用基础研究联合专项基金资助项目 (2014FZ037);

计量
- 文章访问数: 1712
- HTML全文浏览量: 525
- PDF下载量: 61
- 被引次数: 0
出版历程
- 收稿日期: 2017-03-14

Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma by Recombinant Human Vascular Endostatin Combined with Chemoradiotherapy

Funds:

基金：云南省科技厅-昆明医科大学应用基础研究联合专项基金资助项目 (2014FZ037);

摘要

摘要: 目的分析重组人血管内皮抑制素注射液 (恩度) 联合放化疗治疗局部晚期头颈部鳞癌的疗效及安全性.方法收集自2011年7月至2014年6月云南省肿瘤医院收治的局部晚期头颈部鳞癌患者病例资料.放化疗联合恩度组 (恩度组) 有46例患者, 放化疗组 (对照组) 有45例患者.分析比较2组近期疗效及毒副反应比, 总生存率 (OS) 、无疾病进展期 (PFS) .采用美国华盛顿大学生活质量评估比较2组生活质量.结果恩度组与对照组客观反应率分别为87.0%和75.6% (χ2=1.946, P>0.05) , 疾病控制率分别为97.8%和95.6% (χ2=0.368, P>0.05) .恩度组与对照组的中位PFS分别为18.7月和14.7月 (P<0.05) , 中位OS分别为26.8月和23.6月 (P>0.05) , 恩度组与对照组各项不良反应发生率相近.恩度组生活质量评估在心情、焦虑、总分方面高于对照组, 差异有统计学意义 (P<0.05) .结论恩度联合放化疗治疗局部晚期头颈部鳞癌过程中, 在一定程度上增加疗效, 延长了无疾病进展期, 同时不增加不良反应发生率, 提高一定生活质量, 但对于患者的生存期获益仍需进一步研究.
- 头颈部肿瘤 /
- 血管生成抑制剂 /
- 内皮抑素类
Abstract: Objective To analyze the therapeutic efficacy of chemoradiotherapy combined with recombinant human vascular endostatin (endostar) in the treatment of locally advanced head and neck squamous cell carcinoma.Methods From July 2011 to June 2014, data of the patients with locally advanced head and neck squamous cell carcinomas were collected, including 46 patients with chemoradiotherapy combined with endostar and 45 patients with chemoradiotherapy only and the two groups were divided: endostar groups (46 patients) and control group (45 patients) . Objective response rates, disease control rate, overall survival (OS) , and progress free survival (PFS) were compared. Quality of Life Questionnaire from University of Washington was applied to evaluate the life quality of the two groups. Results The objective response rate of endostar group and control group were 87.0% and 75.6% respectively (χ2=1.946, P>0.05) , disease control rate being 97.8% and 95.6% respectively (χ2=0.368, P>0.05) , the median PFS being 18.7 months and 14.7 months respectively (P<0.05) , and median OS being 26.8 months and 23.6 months respectively (P>0.05) . The adverse reaction rate were similar between the two groups. The scores of quality of life, including mood and anxiety domain and total score, in endostar group were higher than those in control group (P <0.05) . Conclusion Endostar combined with chemoradiotherapy can enhance the therapeutic effect of locally advanced head and neck squamous cell carcinoma, prolong free survival progress, improve the quality of life and does not increase adverse reaction rate. But the survival benefit for patients still needs further study.
- Head and Neck Neoplasms /
- Angiogenesis Inhibitors /
- Endostatin

HTML全文

参考文献(12)

[1]	[1]FERLAY J, SHIN H R, BRAY F, et al.Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J].Int J Cancer, 2010, 127 (12) :2893-2917.
[2]	[2]SEIWERT T Y, SALAMA J K, VOKES E E.The chemoradiation paradigm in head and neck cancer[J].Nat Clin Pract Oncol, 2007, 4 (3) :156-171.
[3]曹素杰, 张育红.头颈部鳞癌切除患者近期生活质量的影响因素[J].现代肿瘤医学, 2016, 24 (2) :219-221.
[4]	[4]FOLKMAN J.Tumor angiogenesis:Therapeutrc implication[J].N End J Med, 1971, 285 (21) :1182-1187.
[5]	[5]NEUCHRIST C, EROVIC B M, HANDISURYA A, et al.Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck[J].Laryngoscope, 2001, 111 (10) :1834-1841.
[6]	[6]NEUCHRIST C, EROVIC BM, HANDISURYA A, et al.Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck[J].Head Neck, 2003, 25 (6) :464-474.
[7]	[7]RIEDEL F, GOTTE K, LI M, et al.Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo[J].Int J Oncol, 2003, 23 (3) :577-583.
[8]	[8] KIM Y M, HWANG S, KIM Y M, et al.Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1[J].JBC, 2002, 277 (31) :27872-27879.
[9]	[9]WEN Y E, RANYI LIU, CHANGCHUAN PAN, et al.multicenter randomized phase 2 clinical trial of a recombinant human endostatin adenovirus in patients with advanced head and neck carcinoma[J].Mol Ther, 2014, 22 (6) :1221-1229.
[10]	[10]FURY M G, LEE N Y, SHERMAN E, et al.A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer[J].Cancer, 2012, 118 (20) :5008-5014.
[11]	[11]MA X, YAO Y, YUAN D, et al.Recombinant human endostatinendostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice[J].PLo S One, 2012, 7 (12) :e53449.
[12]牛牛, 李宝兰, 刘朝阳, 等.重组人血管内皮抑制素联合贝伐珠单抗体内抑瘤作用的效果及分析[J].中国肺癌杂志, 2013, 16 (02) :61-66.

相关文章(20)

[1]	李梦, 牛奔, 胡瑾, 马燕琳. 免疫检查点抑制剂引起肿瘤患者甲状腺功能障碍的临床分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240111
[2]	赵玲, 钟洪玲, 高歆茹, 李妹, 毛婷婷, 李荣勇, 柯亭羽. SGLT-2抑制剂延缓糖尿病肾病进展的临床疗效, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230527
[3]	蒋东辉, 陈玉莲, 杨曦, 何晓光, 李玉晓. 头颈部间隙感染病原学及菌属间的易感因素, 昆明医科大学学报.
[4]	陈鑫, 毕姗, 李国萍. 白藜芦醇对头颈部肿瘤防治的研究进展, 昆明医科大学学报.
[5]	林义临, 张宏, 丁筱雪. 脑啡肽酶抑制剂治疗慢性心衰的研究进展, 昆明医科大学学报.
[6]	龚伟, 郭新奎, 王怀杰, 周小倩, 刘强. 无水酒精硬化治疗头颈部动静脉畸形, 昆明医科大学学报.
[7]	李莉, 王佳, 杜娟, 柯亭羽. 精氨酸酶抑制剂与糖尿病血管内皮功能关系的研究进展, 昆明医科大学学报.
[8]	冯林森, 李靖娟, 王羽丰. 重组人血管内皮抑制素联合化疗对晚期乳腺癌疗效的Meta分析, 昆明医科大学学报.
[9]	王志强, 李荣清, 张勇. 头颈部肿瘤在自适应放疗中的研究进展, 昆明医科大学学报.
[10]	邱建武. P38MAPK特异性抑制剂SB203580对肝癌细胞增殖的影响, 昆明医科大学学报.
[11]	宋新焕. 苯基咪唑类Pin1抑制剂的2D-QSAR研究, 昆明医科大学学报.
[12]	谷万港. 基于结构的CXCR4抑制剂的虚拟筛选, 昆明医科大学学报.
[13]	谷万港. 基于结构的HIV-1蛋白酶抑制剂的虚拟筛选, 昆明医科大学学报.
[14]	谷万港. 基于结构的HIV-1蛋白酶抑制剂的虚拟筛选, 昆明医科大学学报.
[15]	孙志敏. 增殖细胞核抗原在头颈部肿瘤中的应用进展, 昆明医科大学学报.
[16]	孙志敏. 增殖细胞核抗原在头颈部肿瘤中的应用进展, 昆明医科大学学报.
[17]	伍治平. 蒿甲醚对大鼠原位脑胶质瘤抑瘤及抗血管生成的实验研究, 昆明医科大学学报.
[18]	李磊. 2003年至2011年云南省肿瘤医院头颈部恶性肿瘤病谱分析, 昆明医科大学学报.
[19]	杨丽华. 抗整合素αⅤβ3单抗抑制上皮性卵巢癌血管及肿瘤生成的实验研究, 昆明医科大学学报.
[20]	. 丝氨酸蛋白酶抑制剂对新生血管抑制作用的研究进展, 昆明医科大学学报.